The Empire Genomics Scientific Advisory Board
Dr. Norma Jean Nowak is the Founder of Empire Genomics, Inc., and served a significant role in the development of the Human Genome Project. Graduating from SUNY Buffalo with a Ph.D. in Experimental Pathology, Dr. Nowak is one of the most renowned researchers in the field of genomics. She has had over 100 peer reviewed publications and works as a Professor at SUNY Buffalo. Dr. Nowak was formerly a leader of the Microarray and Genomics Facility, a collective research lab for Roswell Park Cancer Institute and UB School of Medicine and Biomedical Sciences, since 1999. She devoted fourteen years of research at RPCI to developing clone resources, cloning disease genes, and mapping the human genome. Dr. Nowak was also involved in the NCI extramural Cancer Chromosome Aberration Project for which she developed BAC based array Comparative Genomic Hybridization. Her work has published in the genome issue of Nature Genetics. In addition, Dr. Nowak served a vital role in the GENSAT project which explored gene expression throughout the growth of the central nervous system in mice.
Dr. Michael N. Liebman serves as the Managing Director of Strategic Medicine, Inc., executive Director of the Windber Research Institute, and Chair of the Healthcare Task Force for the SMART program. He was formerly the Director of Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center. Dr. Liebman held the position as Global Head of Computational Genomics at Roche Pharmaceuticals. He was the previous Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals. He also served as the Director of Genomics for Vysis, Inc. in addition to working as the Director of Bioinformatics at the Amoco Technology Company. Dr. Liebman is also an Associate Professor of Pharmacology and Physiology/Biophysics at Mount Sinai School of Medicine. He participates in fifteen international scientific advisory boards and works as a consultant for five pharmaceutical/biotechnological companies. Dr. Liebman concentrates his research efforts on computational simulations of disease development as well as working on transporting bedside problems into the research laboratory in order to enhance patient care.
Dr. Michael J. Becich is a Professor of Biomedical Informatics at the University Of Pittsburgh School Of Medicine and also serves as the Department’s Chairman. He is also Vice Chair, Director and a Professor of Pathology and of Information Sciences and Telecommunications. In addition, he serves as Director of the Benedum Oncology Informatics Center. Dr. Becich attained his MD and a PhD at Northwestern University for Experimental Pathology. He established the country’s first Pathology Informatics fellowship program and the Pathology Informatics 20XX conference. He participates in numerous professional societies and has worked on a number of medical papers and presentations. Dr. Becich’s research focuses on cancer biology, biomedical informatics, and clinical informatics imaging.
Dr. Arthur Brothman is the Medical Director and head of the Cytogenetics and Genomic Microarray Laboratory at the University Of Utah School Of Medicine. He is also a Professor of Pediatrics and of Human Genetics & Pathology. Beginning in the late 1970s, Dr. Brothman worked on numerous research projects, focusing on cytogenetics, chromosomal aberrations, prostate cancer, and genomic technology applications. He and his team are one of the first research organizations to use cytogenomic microarrays (CMA) testing in a clinical setting. He has been a member of the College of American Pathologists and American College of Medical Genetics Cytogenetics Resource Committees. He has also been involved in the Southwest Oncology Group, the Children’s Oncology Group, and a wide array of peer review committees. Dr. Brothman also works on the medical journal, Cancer Genetics, and serves as the publication’s Associate Editor. In addition, he is a participant in a number of Cancer and Genetics Centers, Institutes and Societies.
Have Any Questions Regarding Our Company? Contact Our Team Today